DOCSLIB.ORG

Scientific Programme Friday, 05. July 2019 Registration

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Scientific Programme Friday, 05. July 2019 Registration ISTH 2019: The XXVII Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australia, July 6 - 10, 2019 Scientific Programme Friday, 05. July 2019 Registration 15:00 - 19:00 Main Foyer Registration Page 1 / 209 ISTH 2019: The XXVII Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australia, July 6 - 10, 2019 Scientific Programme Saturday, 06. July 2019 Registration 06:30 - 19:00 Main Foyer Registration Special Session 08:00 - 10:30 Clarendon A/B Trainee Session The Trainee Session of the ISTH 2019 Congress in Melbourne welcomes all trainees and early career professionals interested in Thrombosis and Hemostasis. This 2.5-hour session developed by the ISTH Early Career Committee will provide career mentoring discussions along with round tables with experts on various career and methodology topics and educational tips. Come and start your ISTH Congress by networking and engaging with peers and experts in your field of interest! Chair: Claire McLintock (New Zealand) Chair: Marc Blondon (Switzerland) Introduction and Lecture: Make the Best of Your ISTH Membership 08:00 Speaker: Claire McLintock (New Zealand) Career Mentoring Sessions: Learning from Each Other 08:15 Speaker: David Rabbolini (Australia) Speaker: Vincent Muczynski (United Kingdom) Speaker: Matthew Harper (United Kingdom) Speaker: Eileen Merriman (New Zealand) Speaker: Alisa S. Wolberg (United States) Speaker: Christopher M. Ward (Australia) Transition to Round Tables 09:00 Round Table Discussion 09:05 - 09:30 09:05 How to Become a Good Journal Reviewer Speaker: Mary Cushman (United States) How to Optimize Papers for Publication Speaker: James H. Morrissey (United States) How to Succeed in Getting Funding: Writing a Grant and the Review Process Speaker: Ross Ian Baker (Australia) How to Combine Research and a Laboratory Career Speaker: Emmanuel Favaloro (Australia) How to Combine Research and Clinical Work: Difficulties in Early Career Stage Speaker: Mandy N. Lauw (the Netherlands) Speaker: David Rabbolini (Australia) Page 2 / 209 ISTH 2019: The XXVII Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australia, July 6 - 10, 2019 Scientific Programme How to Transition from a Postdoc Position to a PI: Difficulties for Scientists at an Early Career Level Speaker: Caterina Casari (France) Speaker: Robert Campbell (United States) How to Establish a Career in Thrombosis and Haemostasis in Reach-the- World Countries Speaker: Pedro Henrique Fernandes do Carmo Las Casas (Brazil) Speaker: Pantep Angchaisuksiri (Thailand) Tips for a Good CV / Cover Letter / Recommendation Speaker: Christopher M. Ward (Australia) Tips for a Good Short Oral Presentation Speaker: Peter Lenting (France) How to Improve Your Poster Presentation Speaker: Geoffrey Barnes (United States) How to Be a Good Mentee Speaker: Alisa S. Wolberg (United States) Speaker: Deborah M. Siegal (Canada) How to Maintain a Healthy Work-Life Balance Speaker: Claire McLintock (New Zealand) Speaker: Eileen Merriman (New Zealand) Tips and Pitfalls for Systematic Reviews and Meta-Analyses Speaker: Marc Carrier (Canada) Minimizing Biases in Observational Studies Speaker: Marc Blondon (Switzerland) How to Be a Good Session Moderator Speaker: Walter Ageno (Italy) Break and Networking - 09:30 - 09:50 09:30 Round Table Discussion 09:50 - 10:15 09:50 How to Become a Good Journal Reviewer Speaker: Mary Cushman (United States) How to Optimize Papers for Publication Speaker: James H. Morrissey (United States) How to Succeed in Getting Funding: Writing a Grant and the Review Process Speaker: Ross Ian Baker (Australia) How to Combine Research and a Laboratory Career Speaker: Emmanuel Favaloro (Australia) How to Combine Research and Clinical Work: Difficulties in Early Career Stage Speaker: Mandy N. Lauw (the Netherlands) Speaker: David Rabbolini (Australia) Page 3 / 209 ISTH 2019: The XXVII Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australia, July 6 - 10, 2019 Scientific Programme How to Transition from a Postdoc Position to a PI: Difficulties for Scientists at an EC Level Speaker: Caterina Casari (France) Speaker: Robert Campbell (United States) How to Establish a Career in Thrombosis and Haemostasis in Reach-the- World Countries Speaker: Pantep Angchaisuksiri (Thailand) Speaker: Pedro Henrique Fernandes do Carmo Las Casas (Brazil) Tips for a Good CV / Cover Letter / Recommendation Speaker: Christopher M. Ward (Australia) Tips for a Good Short Oral Presentation Speaker: Peter Lenting (France) How to Improve Your Poster Presentation Speaker: Geoffrey Barnes (United States) How to Be a Good Mentee Speaker: Alisa S. Wolberg (United States) Speaker: Deborah M. Siegal (Canada) How to Maintain a Healthy Work-Life Balance Speaker: Claire McLintock (New Zealand) Speaker: Eileen Merriman (New Zealand) Tips and Pitfalls for Systematic Reviews and Meta-Analyses Speaker: Marc Carrier (Canada) Minimizing Biases in Observational Studies Speaker: Marc Blondon (Switzerland) How to Be a Good Session Moderator Speaker: Walter Ageno (Italy) How to Become a Good Educator 10:15 Speaker: Renee Eslick (Australia) Supported Symposia 11:30 - 12:45 Meeting Room 203/204 Supported Symposium Title: Transforming Research Into Clinical Reality: Takeda’s Gene Therapy Program in Hemophilia This session is supported by Takeda Please view the program here Supported Symposia 11:30 - 12:45 Meeting Room 210/211 Supported Symposium Title: The Role of the Protein C System in a Rare Disorder and its Impact in Critical Care This session is supported by Takeda Please view the program here Page 4 / 209 ISTH 2019: The XXVII Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australia, July 6 - 10, 2019 Scientific Programme Supported Symposia 11:30 - 12:45 Meeting Room 212/213 Supported Symposium Title: The Evolution of Turning Genes Into Medicine: Leveraging Innovation To Create a Path Forward This session is supported by Spark Therapeutics, Inc. Please view the program here Supported Symposia 11:30 - 12:45 Meeting Room 219/220 Supported Symposium Title: Understanding the Outcomes of Anticoagulation: Insights From the GARFIELD Registries This session is supported by TRI Please visit here Supported Symposia 11:30 - 12:45 Meeting Room 105 Supported Symposium Title: Navigating the New World: Haemophilia in the 21st Century This session is supported by Sanofi Genzyme Please view the program here Supported Symposia 11:30 - 12:45 Meeting Room 106 Supported Symposium Title: Defining a New Paradigm for the Management of Acquired Thrombotic Thrombocytopenic Purpura This session is supported by Sanofi Genzyme Please view the program here Supported Symposia 11:30 - 12:45 Meeting Room 109 Supported Symposium Title: Inhibitors: Prevention and Evolving Treatment Paradigms This session is supported by GRIFOLS Please view the program here Supported Symposia 11:30 - 12:45 Meeting Room 110 Supported Symposium Title: A Decade of Innovation: from DOACs to Reversal Agents This session is supported by Boehringer Ingelheim Please view the program here Page 5 / 209 ISTH 2019: The XXVII Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australia, July 6 - 10, 2019 Scientific Programme Oral Communication Session 13:00 - 14:15 Melbourne Room 1 OC 02, New Antithrombotic Targets Chair: Robert Flaumenhaft (United States) Chair: Freda J. Passam (Australia) Thymidine Phosphorylase Is a Novel Anti-atherothrombotic Target 13:00 Speaker: Wei Li (United States) The Cyclooxygenase-1/Microsomal Prostaglandin E 13:15 Synthase-1/Endothelial EP4 Receptor Pathway Constrains Myocardial Ischemia-Reperfusion Injury: New Insight into Microcirculation Speaker: Miao Wang (China) Recombinant Factor VII Activating Protease (FSAP) Decreases Infarct 13:30 Volume and Improves Neurological Outcome in two Different Mouse Models of Ischemic Stroke Speaker: Jeong Yeon Kim (Norway) Patients with Atrial Fibrillation Overexpress Fibrin-binding Platelet 13:45 Receptor GPVI-dimer. A Future Anti-thrombotic Target? Speaker: Isuru Induruwa (United Kingdom) New Peptide-agonist of PAR1 Demonstrates Neuroprotective Effect at the 14:00 Photothrombosis-induced Damage of Mouse Brain Speaker: Liubov Gorbacheva (Russian Federation) Oral Communication Session 13:00 - 14:15 Melbourne Room 2 OC 01, Gene Therapy Clinical Chair: Guy Young (United States) Chair: Julie Curtin (Australia) AMT-061 (AAV5-Padua hFIX variant) an Enhanced Vector for Gene 13:00 Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Follow- up up to 9 Months in a Phase 2b Trial Speaker: Adam Giermasz (United States) Initial Results of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose- 13:15 Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Subjects with Severe Hemophilia A Speaker: Barbara A. Konkle (United States) Health-related Quality of Life Improvements in Adult Haemophilia B 13:30 Patients at One Year Follow-up after Receiving SPK-9001 Gene Transfer Speaker: Sylvia von Mackensen (Germany) Stable Expression of FIX and Maintained Reductions in Bleeding and 13:45 Factor IX Consumption Following AMT-060 Gene Therapy with up to 3.5 Years of Follow Up in Adults with Severe or Moderate-Severe Hemophilia B Speaker: Frank Leebeek (the Netherlands) Page 6 / 209 ISTH 2019: The XXVII Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australia, July 6 - 10, 2019 Scientific Programme Oral Communication Session 13:00 - 14:15 Meeting
Load more

Recommended publications
  • The Role of Streptococcal and Staphylococcal Exotoxins and Proteases in Human Necrotizing Soft Tissue Infections
    toxins Review The Role of Streptococcal and Staphylococcal Exotoxins and Proteases in Human Necrotizing Soft Tissue Infections Patience Shumba 1, Srikanth Mairpady Shambat 2 and Nikolai Siemens 1,* 1 Center for Functional Genomics of Microbes, Department of Molecular Genetics and Infection Biology, University of Greifswald, D-17489 Greifswald, Germany; [email protected] 2 Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, CH-8091 Zurich, Switzerland; [email protected] * Correspondence: [email protected]; Tel.: +49-3834-420-5711 Received: 20 May 2019; Accepted: 10 June 2019; Published: 11 June 2019 Abstract: Necrotizing soft tissue infections (NSTIs) are critical clinical conditions characterized by extensive necrosis of any layer of the soft tissue and systemic toxicity. Group A streptococci (GAS) and Staphylococcus aureus are two major pathogens associated with monomicrobial NSTIs. In the tissue environment, both Gram-positive bacteria secrete a variety of molecules, including pore-forming exotoxins, superantigens, and proteases with cytolytic and immunomodulatory functions. The present review summarizes the current knowledge about streptococcal and staphylococcal toxins in NSTIs with a special focus on their contribution to disease progression, tissue pathology, and immune evasion strategies. Keywords: Streptococcus pyogenes; group A streptococcus; Staphylococcus aureus; skin infections; necrotizing soft tissue infections; pore-forming toxins; superantigens; immunomodulatory proteases; immune responses Key Contribution: Group A streptococcal and Staphylococcus aureus toxins manipulate host physiological and immunological responses to promote disease severity and progression. 1. Introduction Necrotizing soft tissue infections (NSTIs) are rare and represent a more severe rapidly progressing form of soft tissue infections that account for significant morbidity and mortality [1].
    [Show full text]
  • Clinical Commissioning Policy: Susoctocog Alfa for Treating Bleeding Episodes in People with Acquired Haemophilia a (All Ages)
    Clinical Commissioning Policy: Susoctocog alfa for treating bleeding episodes in people with acquired haemophilia A (all ages) NHS England Reference: 170061P 1 NHS England INFORMATION READER BOX Directorate Medical Operations and Information Specialised Commissioning Nursing Trans. & Corp. Ops. Commissioning Strategy Finance Publications Gateway Reference: 07603 Document Purpose Policy Clinical commissioning policy: Susoctocog alfa for treating bleeding Document Name episodes in people with acquired haemophilia A (all ages) Author Specialised Commissioning Team Publication Date 29 June 2018 Target Audience CCG Clinical Leaders, Care Trust CEs, Foundation Trust CEs , Medical Directors, Directors of PH, Directors of Nursing, NHS England Regional Directors, NHS England Directors of Commissioning Operations, Directors of Finance, NHS Trust CEs Additional Circulation #VALUE! List Description Routinely Commissioned - NHS England will routinely commission this specialised treatment in accordance with the criteria described in this policy. Cross Reference 0 Superseded Docs 0 (if applicable) Action Required 0 Timing / Deadlines By 00 January 1900 (if applicable) Contact Details for [email protected] further information 0 0 0 0 0 0 Document Status This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of this document are not controlled. As a controlled document, this document should not be saved onto local or network drives but should always be accessed from the intranet. 2 Standard Operating Procedure: Clinical Commissioning Policy: Susoctocog alfa for treating bleeding episodes in people with acquired haemophilia A (all ages) First published: June 2018 Prepared by the National Institute for Health and Care Excellence (NICE) Commissioning Support Programme Published by NHS England, in electronic format only.
    [Show full text]
  • Role of Vegetation-Associated Protease Activity in Valve Destruction in Human Infective Endocarditis
    Role of Vegetation-Associated Protease Activity in Valve Destruction in Human Infective Endocarditis Ghada Al-Salih1, Nawwar Al-Attar2,3, Sandrine Delbosc1, Liliane Louedec1, Elisabeth Corvazier1, Ste´phane Loyau1, Jean-Baptiste Michel1,3, Dominique Pidard1,4, Xavier Duval5, Olivier Meilhac1,3,6* 1 INSERM U698, Paris, France, 2 Cardiovascular Surgery Department, Bichat Hospital, AP-HP, Paris, France, 3 University Paris Diderot, Sorbonne Paris Cite´, Paris, France, 4 Institut National des Sciences du Vivant, Centre National de la Recherche Scientifique, Paris, France, 5 INSERM CIC 007, Paris, France, 6 Bichat Stroke Centre, AP-HP, Paris, France Abstract Aims: Infective endocarditis (IE) is characterized by septic thrombi (vegetations) attached on heart valves, consisting of microbial colonization of the valvular endocardium, that may eventually lead to congestive heart failure or stroke subsequent to systemic embolism. We hypothesized that host defense activation may be directly involved in tissue proteolytic aggression, in addition to pathogenic effects of bacterial colonization. Methods and Results: IE valve samples collected during surgery (n = 39) were dissected macroscopically by separating vegetations (VG) and the surrounding damaged part of the valve from the adjacent, apparently normal (N) valvular tissue. Corresponding conditioned media were prepared separately by incubation in culture medium. Histological analysis showed an accumulation of platelets and polymorphonuclear neutrophils (PMNs) at the interface between the VG and the underlying tissue. Apoptotic cells (PMNs and valvular cells) were abundantly detected in this area. Plasminogen activators (PA), including urokinase (uPA) and tissue (tPA) types were also associated with the VG. Secreted matrix metalloproteinase (MMP) 9 was also increased in VG, as was leukocyte elastase and myeloperoxidase (MPO).
    [Show full text]
  • Tavalisse™ (Fostamatinib) (Oral) Document Number: IC-0361 Last Review Date: 02/02/2021 Date of Origin: 06/01/2018 Dates Reviewed: 06/2018, 02/2019, 02/2020, 02/2021
    Tavalisse™ (fostamatinib) (Oral) Document Number: IC-0361 Last Review Date: 02/02/2021 Date of Origin: 06/01/2018 Dates Reviewed: 06/2018, 02/2019, 02/2020, 02/2021 I. Length of Authorization Coverage is provided for six months and may be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: 100 mg tablets – 2 tablets per day 150 mg tablets – 2 tablets per day B. Max Units (per dose and over time) [HCPCS Unit]: 300 mg daily III. Initial Approval Criteria 1,2 Coverage is provided in the following conditions: Patient is at least 18 years of age; AND Universal Criteria 1 Patient is not receiving a thrombopoietin receptor agonist or mimetic (e.g., romiplostim, eltrombopag, lusutrombopag, avatrombopag, etc.); AND Laboratory values are current (i.e., drawn within the previous 28 days); AND Fostamatinib is not being used to attempt to normalize platelet count; AND Patient will avoid concomitant therapy with any of the following: o Coadministration with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ketoconazole, etc.), or if therapy is unavoidable, the patient will be monitored closely for adverse reaction and/or dose modifications will be implemented; AND o Coadministration with strong CYP3A inducers (e.g., rifampin, carbamazepine, St. John’s Wort, etc.); AND Chronic Immune Thrombocytopenia (ITP) † 1-5 Patient has had persistent/chronic ITP for at least 3 months; AND Proprietary & Confidential © 2021 Magellan Health, Inc. Patient has previously failed any of the following treatments for ITP: Patient has failed previous therapy with corticosteroids (i.e., patient had no response to at least a 3-month trial or is corticosteroid-dependent); OR Patient has failed previous therapy with immunoglobulins; OR Patient has had a splenectomy; OR Patient has failed previous therapy with a thrombopoietin receptor agonist; AND The patient is at increased risk for bleeding as indicated by platelet count of less than 30 × 109/L (30,000/mm³) † FDA Approved Indication(s) IV.
    [Show full text]
  • Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases
    International Journal of Molecular Sciences Review Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases Peter Goettig Structural Biology Group, Faculty of Molecular Biology, University of Salzburg, Billrothstrasse 11, 5020 Salzburg, Austria; [email protected]; Tel.: +43-662-8044-7283; Fax: +43-662-8044-7209 Academic Editor: Cheorl-Ho Kim Received: 30 July 2016; Accepted: 10 November 2016; Published: 25 November 2016 Abstract: Posttranslational modifications are an important feature of most proteases in higher organisms, such as the conversion of inactive zymogens into active proteases. To date, little information is available on the role of glycosylation and functional implications for secreted proteases. Besides a stabilizing effect and protection against proteolysis, several proteases show a significant influence of glycosylation on the catalytic activity. Glycans can alter the substrate recognition, the specificity and binding affinity, as well as the turnover rates. However, there is currently no known general pattern, since glycosylation can have both stimulating and inhibiting effects on activity. Thus, a comparative analysis of individual cases with sufficient enzyme kinetic and structural data is a first approach to describe mechanistic principles that govern the effects of glycosylation on the function of proteases. The understanding of glycan functions becomes highly significant in proteomic and glycomic studies, which demonstrated that cancer-associated proteases, such as kallikrein-related peptidase 3, exhibit strongly altered glycosylation patterns in pathological cases. Such findings can contribute to a variety of future biomedical applications. Keywords: secreted protease; sequon; N-glycosylation; O-glycosylation; core glycan; enzyme kinetics; substrate recognition; flexible loops; Michaelis constant; turnover number 1.
    [Show full text]
  • PAGE Program 2019
    PAGE Program 2019 Tuesday 11 June 14:00-18:00 Registration at the Conference Venue 18:00-19:30 Welcome reception with drinks and light snacks (no dinner) Wednesday 12 June 08:00-08:45 Registration 08:45-09:00 Welcome and Introduction 09:00-09:45 Keynote lecture Chair: Dinesh De Alwis Pharmacometrics: A shot in the arm for vaccine discovery and 09:00-09:45 Jeff Sachs development ~or~ Vaccines are not immune to the charms of pharmacometrics 09:45-09:50 PAGE scientific program Siv Jönsson 09:50-11:15 Coffee break, Poster and Software session I Posters in Group I (with poster numbers starting with I-) are accompanied by their presenter 11:15-12:15 Infectious diseases Chair: France Mentré Stratified medicine approaches for drug susceptible tuberculosis 11:15-11:35 Marjorie Imperial patients Repeated time-to-event models support that Pseudomonas 11:35-11:55 Stefanie Hennig aeruginosa infection increase the risk of acquiring Aspergillus in young children with cystic fibrosis María García- Individual level data meta-analysis from HIV pre-exposure 11:55-12:15 Cremades prophylaxis (PrEP) clinical trials 12:15-13:45 Lunch 13:45-14:30 Tutorial Chair: Mats Karlsson 13:45-14:30 Nicky Best Use of informative priors in model-informed drug development Page | 1 Chairs: Mats Karlsson, 14:30-15:10 Machine learning in oncology Paolo Magni Machine learning combined to mechanistic modeling of 14:30-14:50 Chiara Nicolò differential effects of neoadjuvant sunitinib on primary tumor and metastatic growth Machine learning versus mechanistic modeling for prediction
    [Show full text]
  • Blood Modifier Agents Policy #: Rx.01.208
    Pharmacy Policy Bulletin Title: Blood Modifier Agents Policy #: Rx.01.208 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some medications may be subject to precertification, age, quantity, or formulary restrictions (ie limits on non-preferred drugs). Individual member benefits must be verified. This pharmacy policy document describes the status of pharmaceutical information and/or technology at the time the document was developed. Since that time, new information relating to drug efficacy, interactions, contraindications, dosage, administration routes, safety, or FDA approval may have changed. This Pharmacy Policy will be regularly updated as scientific and medical literature becomes available. This information may include new FDA-approved indications, withdrawals, or other FDA alerts. This type of information is relevant not only when considering whether this policy should be updated, but also when applying it to current requests for coverage. Members are advised to use participating pharmacies in order to receive the highest level of benefits. Intent: The intent of this policy is to communicate the medical necessity criteria for eltrombopag olamine (Promacta®), fostamatinib disodium (Tavalisse™), avatrombopag (Doptelet®), lusutrombopag (Mulpleta®) as provided under the member's prescription drug benefit. Description: Idiopathic thrombocytopenia purpura (ITP): ITP is an immune disorder in which the blood doesn't clot normally. ITP can cause excessive bruising and bleeding and can be characterized as an unusually low level of platelets, or thrombocytes, in the blood results in ITP. Thrombocytopenia in patients with hepatitis C: Thrombocytopenia can occur in patients with chronic hepatitis C virus (HCV) infection.
    [Show full text]
  • Human and Recombinat Coagulation Factor VIII
    08 July 2016 EMA/PRAC/471535/2016 PRAC List of questions To be addressed by the marketing authorisation holder(s) for human and recombinant coagulation factor VIII containing medicinal products Referral under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data Procedure number: EMEA/H/A-31/1448 Advate EMEA/H/C/0520/A31/0078 Elocta EMEA/H/C/3964/A31/0006 Helixate Nexgen EMEA/H/C/0276/A31/0178 Iblias EMEA/H/C/4147/A31/0002 Kogenate EMEA/H/C/0275/A31/0185 Kovaltry EMEA/H/C/3825/A31/0004 Novoeight EMEA/H/C/2719/A31/0014 Nuwiq EMEA/H/C/2813/A31/0015 Obizur EMEA/H/C/2792/A31/0003 Refacto AF EMEA/H/C/0232/A31/0134 Voncento EMEA/H/C/2493/A31/0022 Active substances: human coagulation factor VIII; efmoroctocog alfa; moroctocog alfa; octocog alfa; simoctocog alfa; susoctocog alfa; turoctocog alfa 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 1. Background Today’s standard treatment of congenital haemophilia (and acquired haemophilia A) is based on prophylactic or on-demand replacement therapy with coagulation factor VIII (FVIII), either with plasma derived or with recombinant FVIII products. Principally both substance classes may be used for prophylactic treatment as well as for therapeutic treatment in case of spontaneous bleedings. Inhibitor development in haemophilia A patients receiving FVIII products mostly occurs in previously untreated or minimally treated patients (PUPs), who are still within the first 50 days of exposure to the treatment.
    [Show full text]
  • Highly Potent and Selective Plasmin Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold Attenuate Fibrinolysis in Plasma
    Highly Potent and Selective Plasmin Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold Attenuate Fibrinolysis in Plasma Joakim E. Swedberg,‡† Guojie Wu,§† Tunjung Mahatmanto,‡# Thomas Durek,‡ Tom T. Caradoc-Davies,∥ James C. Whisstock,§* Ruby H.P. Law§* and David J. Craik‡* ‡Institute for Molecular Bioscience, The University of Queensland, Brisbane QLD 4072, Australia §ARC Centre of Excellence in Advanced Molecular Imaging, Department of Biochemistry and Molecular Biology, Biomedical Discovery Institute, Monash University, VIC 3800, Australia. ∥Australian Synchrotron, 800 Blackburn Road, Clayton, Melbourne, VIC 3168, Australia. †J.E.S. and G.W. contributed equally to this work. Keywords: Antifibrinolytics; Fibrinolysis; Inhibitors; Peptides; Plasmin ABSTRACT Antifibrinolytic drugs provide important pharmacological interventions to reduce morbidity and mortality from excessive bleeding during surgery and after trauma. Current drugs used for inhibiting the dissolution of fibrin, the main structural component of blood clots, are associated with adverse events due to lack of potency, high doses and non-selective inhibition mechanisms. These deficiencies warrant the development of a new generation highly potent and selective fibrinolysis inhibitors. Here we use the 14-amino acid backbone-cyclic sunflower trypsin inhibitor-1 scaffold to design a highly potent (Ki = 0.05 nM) inhibitor of the primary serine protease in fibrinolysis, plasmin. This compound displays a million-fold selectivity over other serine proteases in blood, inhibits fibrinolysis in plasma more effectively than the gold-standard therapeutic inhibitor aprotinin and is a promising candidate for development of highly specific fibrinolysis inhibitors with reduced side effects. 1 INTRODUCTION The physiological process of fibrinolysis regulates the dissolution of blood clots and thrombosis.
    [Show full text]
  • Multiple Technology Appraisal Avatrombopag and Lusutrombopag
    Multiple Technology Appraisal Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520] Committee papers © National Institute for Health and Care Excellence 2019. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE MULTIPLE TECHNOLOGY APPRAISAL Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520] Contents: 1 Pre-meeting briefing 2 Assessment Report prepared by Kleijnen Systematic Reviews 3 Consultee and commentator comments on the Assessment Report from: • Shionogi 4 Addendum to the Assessment Report from Kleijnen Systematic Reviews 5 Company submission(s) from: • Dova • Shionogi 6 Clarification questions from AG: • Questions to Shionogi • Clarification responses from Shionogi • Questions to Dova • Clarification responses from Dova 7 Professional group, patient group and NHS organisation submissions from: • British Association for the Study of the Liver (BASL) The Royal College of Physicians supported the BASL submission • British Society of Gastroenterology (BSG) 8 Expert personal statements from: • Vanessa Hebditch – patient expert, nominated by the British Liver Trust • Dr Vickie McDonald – clinical expert, nominated by British Society for Haematology • Dr Debbie Shawcross – clinical expert, nominated by Shionogi © National Institute for Health and Care Excellence 2019. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner. MTA: avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure Pre-meeting briefing © NICE 2019.
    [Show full text]
  • Advances in Hepatology and Robley Rex VAMC NAFLD/NASH
    Luis S. Marsano, MD, FAASLD, FACG, AGAF, FASGE Professor of Medicine, Director of Hepatology University of Louisville Advances in Hepatology and Robley Rex VAMC NAFLD/NASH Coagulation in Cirrhosis Topics Hepatocellular Carcinoma Miscellaneous Definitions of NAFLD, NAFL and NASH Nonalcoholic fatty liver disease (NAFLD) a. Evidence of hepatic steatosis by imaging or histology b. Lack of secondary causes of hepatic fat accumulation Non-alcoholic steato-hepatitis (NASH) Nonalcoholic fatty liver (NAFL) ≥5% hepatic steatosis and ≥5% hepatic steatosis without inflammation with hepatocyte injury evidence of hepatocellular injury in (eg, ballooning), with or without any the form of hepatocyte ballooning fibrosis Chalasani N, et al. Hepatology. 2017. doi:10.1002/hep.29367 Estimated Global Prevalence of NAFLD: 25% 24% 24% 27% 32% 13% 31% Meta-analysis: NAFLD diagnosed by imaging (US, CT, MRI/SPECT; n=45 studies). Younossi ZM, et al. Hepatology. 2016;64:73-84. 4 Estimated Global NASH Prevalence 6-7% 7-8% 5-6% 8-10% 3-4% 8-9% NASH is Prevalent Globally *25-30% of NAFLD prevalence assumed to be NASH in the above map. 5 Younossi ZM, et al. Hepatology2016;64:73-84; Williams CD, et al. Gasteoenterology 2011;140:124-131. Estimated NASH Prevalence in the U.S. ~30% of U.S. adult population Non-Alcoholic estimated to have NAFLD Fatty Liver Disease NAFLD 83.1 Million Non-Alcoholic Steatohepatitis NASH 16.5 Million Disease Spectrum Disease NASH with 3.3 Million F3/F4 Fibrosis F3 = 2 M; F4 = 1.3 M Unmet Need Estes, et al. Hepatology. 2017. doi:10.1002/hep.29466.
    [Show full text]
  • Nye Legemidler Som Ikke Har Markedsføringstillatelse for Legemidler Oppført På Listen Gjelder Retningslinjens Vilkår Uavhengig Av Indikasjon for Bruken
    Nye legemidler som ikke har markedsføringstillatelse For legemidler oppført på listen gjelder retningslinjens vilkår uavhengig av indikasjon for bruken. Oppdatert: 13.11.2018 Orphan medicinal Indikasjon per nå. product (* Se (Samt mulig andre indikasjoner i informasjon Oppført på Virkestoff fremtiden.) nederst) listen Depatuximab mafodotin Treatment of glioblastoma (GBM) nov.18 Alpelisib Breast cancer; advanced hormone receptor positive (HR+), HER2-negative in men and postmenopausal women - second-line with fulvestrant okt.18 Omadacycline tosylate Treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure okt.18 Siponimod Treatmentinfections (ABSSSI) of secondary in adults progressive multiple sclerosis (SPMS) okt.18 autologous cd34+ cell enriched Treatment of transfusion-dependent β- population that contains thalassaemia (TDT) hematopoietic stem cells transduced with lentiglobin bb305 lentiviral vector encoding the beta-a-t87q-globin gene x okt.18 Fostamatinib Indicated for the treatment of thrombocytopenia okt.18 Dolutegravir / lamivudine Treatment of Human Immunodeficiency Virus type 1 (HIV-1) okt.18 Adeno-associated viral vector Treatment of paediatric patients serotype 9 containing the diagnosed with spinal muscular atrophy human SMN gene (AVXS-101) Type 1 okt.18 Treatment of non-neurological manifestations of acid sphingomyelinase Olipudase alfa deficiency okt.18 Treatment of adult and paediatric patients with locally advanced or Larotrectinib metastatic solid tumours x sep.18 Treatment
    [Show full text]